Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nidan Laboratories and Healthcare ROE % Adjusted to Book Value Chart
NSE:NIDAN vs TMO, DHR, IDXX: ROE % Adjusted to Book Value Comparison
For the Diagnostics & Research subindustry, Nidan Laboratories and Healthcare's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nidan Laboratories and Healthcare ROE % Adjusted to Book Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Nidan Laboratories and Healthcare's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Nidan Laboratories and Healthcare's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 7.59% mean?
Nidan Laboratories and Healthcare (NSE:NIDAN) has a ROE % Adjusted to Book Value of 7.59% as of Mar. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Nidan Laboratories and Healthcare and its competitors.
Is Nidan Laboratories and Healthcare's ROE % Adjusted to Book Value too high?
Nidan Laboratories and Healthcare's current ROE % Adjusted to Book Value is 7.59%. Overall, Nidan Laboratories and Healthcare has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Nidan Laboratories and Healthcare's ROE % Adjusted to Book Value compare to TMO and DHR?
Nidan Laboratories and Healthcare's ROE % Adjusted to Book Value of 7.59% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Diagnostics & Research company?
A good ROE % Adjusted to Book Value depends on the Medical Diagnostics & Research industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Nidan Laboratories and Healthcare and its competitors. Nidan Laboratories and Healthcare's current ROE % Adjusted to Book Value is 7.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nidan Laboratories and Healthcare stock overvalued right now?
Nidan Laboratories and Healthcare (NSE:NIDAN) has a current ROE % Adjusted to Book Value of 7.59%. The current ROE % Adjusted to Book Value is 7.59%. Nidan Laboratories and Healthcare's overall GF Score™ is 67/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Nidan Laboratories and Healthcare (NSE:NIDAN), the current ROE % Adjusted to Book Value is 7.59% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nidan Laboratories and Healthcare Business Description
Nidan Laboratories and Healthcare Ltd offer diagnostic services including radiology, neurology, cardiology, dental as well as pathology services. The company provides pathology tests ranging from basic biochemistry and clinical pathology to cytogenetic and high-end molecular diagnostic tests, and radiology tests ranging from basic echocardiograms, X-Rays, and ultrasounds to radiology tests including computerized tomography scans, magnetic resonance imaging scans.
67GF Score
Get the complete analysis for NSE:NIDAN
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NIDAN has been successfully added to your 
